📊 CUBT Key Takeaways
Is Curative Biotechnology Inc (CUBT) a Good Investment?
Curative Biotechnology Inc presents an uninvestable opportunity due to complete absence of financial data across all fundamental metrics. The company reports no revenue, no profitability data, and no operational cash flow, indicating either pre-revenue stage, operational distress, or severe reporting deficiencies that prevent fundamental analysis.
Based on the latest available EDGAR financials, Curative Biotechnology remains a pre-revenue development-stage biotech with no operating revenue, recurring net losses, negative equity, and an auditor going-concern warning. While losses and operating cash burn improved in 2024 and in the quarter ended March 31, 2025, the balance sheet is extremely weak, with cash far below current liabilities and continued dependence on outside financing. The December 22, 2025 withdrawal of its S-1 also increases concern about funding access rather than underlying business traction.
Why Buy Curative Biotechnology Inc Stock? CUBT Key Strengths
- No strengths identified
- Net loss improved to about $3.4 million in 2024 from about $4.0 million in 2023
- Operating cash burn improved, with Q1 2025 operating cash outflow of about $185 thousand versus about $261 thousand in Q1 2024
- Interest expense and one-time debt extinguishment pressure were lower in 2024 than in 2023
CUBT Stock Risks: Curative Biotechnology Inc Investment Risks
- Complete absence of financial reporting - no revenue, assets, or cash flow data available
- No operational metrics to assess business viability or growth trajectory
- Zero insider activity in last 90 days suggests potential management disengagement or inactive company status
- OTC exchange listing compounds liquidity and transparency concerns
- Insufficient data points (only 1 metric available) prevents meaningful fundamental analysis
- No revenue or gross profit, so there is still no evidence of commercial validation or self-sustaining growth
- Severe liquidity stress: about $218 thousand of cash versus about $7.3 million of current liabilities at March 31, 2025, plus negative stockholders' equity
- Going-concern uncertainty and ongoing reliance on external capital raise material refinancing and dilution risk
Key Metrics to Watch
- Revenue generation and trend trajectory
- Cash position and burn rate relative to operations
- Product pipeline status and clinical development milestones
- Quarterly cash balance versus operating cash burn and current liabilities
- Any transition from pre-revenue status to recurring revenue or meaningful clinical/commercial milestone monetization
Curative Biotechnology Inc (CUBT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CUBT Profit Margin, ROE & Profitability Analysis
CUBT vs Healthcare Sector: How Curative Biotechnology Inc Compares
How Curative Biotechnology Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Curative Biotechnology Inc Stock Overvalued? CUBT Valuation Analysis 2026
Based on fundamental analysis, Curative Biotechnology Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Curative Biotechnology Inc Balance Sheet: CUBT Debt, Cash & Liquidity
CUBT Revenue Growth, EPS Growth & YoY Performance
CUBT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Curative Biotechnology Inc (CIK: 0001400271)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CUBT
What is the AI rating for CUBT?
Curative Biotechnology Inc (CUBT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CUBT's key strengths?
Claude: . ChatGPT: Net loss improved to about $3.4 million in 2024 from about $4.0 million in 2023. Operating cash burn improved, with Q1 2025 operating cash outflow of about $185 thousand versus about $261 thousand in Q1 2024.
What are the risks of investing in CUBT?
Claude: Complete absence of financial reporting - no revenue, assets, or cash flow data available. No operational metrics to assess business viability or growth trajectory. ChatGPT: No revenue or gross profit, so there is still no evidence of commercial validation or self-sustaining growth. Severe liquidity stress: about $218 thousand of cash versus about $7.3 million of current liabilities at March 31, 2025, plus negative stockholders' equity.
What is CUBT's revenue and growth?
Curative Biotechnology Inc reported revenue of N/A.
Does CUBT pay dividends?
Curative Biotechnology Inc does not currently pay dividends.
Where can I find CUBT SEC filings?
Official SEC filings for Curative Biotechnology Inc (CIK: 0001400271) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CUBT's EPS?
Curative Biotechnology Inc has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CUBT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Curative Biotechnology Inc has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CUBT stock overvalued or undervalued?
Valuation metrics for CUBT: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CUBT stock in 2026?
Our dual AI analysis gives Curative Biotechnology Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CUBT's free cash flow?
Curative Biotechnology Inc's operating cash flow is N/A, with capital expenditures of N/A.
How does CUBT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).